Wainua granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.1 Wainua is the only…

Read MoreWainua granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo (TSE: 4568) and Merck, known as MSD outside of the United States and Canada, (NYSE: MEK) announced today that the U.S. Food and Drug Administration (FDA) has accepted…

Read MorePatritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Blackstone

Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regarding ensitrelvir fumaric acid, a treatment drug for the novel coronavirus infection (COVID-19)

Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Ping An-Shionogi (Hong Kong) Limited (Head Office: Hong Kong, China; Chairman and Chief…

Read MoreExecution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regarding ensitrelvir fumaric acid, a treatment drug for the novel coronavirus infection (COVID-19)

Two Phase 3 Trials of Datopotamab Deruxtecan Plus DurvalumabInitiated in Patients Across Two Breast Cancer Subtypes

The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd)…

Read MoreTwo Phase 3 Trials of Datopotamab Deruxtecan Plus DurvalumabInitiated in Patients Across Two Breast Cancer Subtypes

Decision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free

 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its decision today to invest in its Bio drug substance (DS) manufacturing facility “UK3” in the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing…

Read MoreDecision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free